Endotyping in ARDS: one step forward in precision medicine.


Journal

European journal of medical research
ISSN: 2047-783X
Titre abrégé: Eur J Med Res
Pays: England
ID NLM: 9517857

Informations de publication

Date de publication:
14 May 2024
Historique:
received: 06 04 2023
accepted: 30 04 2024
medline: 15 5 2024
pubmed: 15 5 2024
entrez: 14 5 2024
Statut: epublish

Résumé

The Berlin definition of acute respiratory distress syndrome (ARDS) includes only clinical characteristics. Understanding unique patient pathobiology may allow personalized treatment. We aimed to define and describe ARDS phenotypes/endotypes combining clinical and pathophysiologic parameters from a Canadian ARDS cohort. A cohort of adult ARDS patients from multiple sites in Calgary, Canada, had plasma cytokine levels and clinical parameters measured in the first 24 h of ICU admission. We used a latent class model (LCM) to group the patients into several ARDS subgroups and identified the features differentiating those subgroups. We then discuss the subgroup effect on 30 day mortality. The LCM suggested three subgroups (n ARDS subgrouping using biomarkers and clinical characteristics is useful for categorizing a heterogeneous condition into several homogenous patient groups. This study found three ARDS subgroups using LCM; each subgroup has a different level of mortality. This model may also apply to developing further trial design, prognostication, and treatment selection.

Sections du résumé

BACKGROUND BACKGROUND
The Berlin definition of acute respiratory distress syndrome (ARDS) includes only clinical characteristics. Understanding unique patient pathobiology may allow personalized treatment. We aimed to define and describe ARDS phenotypes/endotypes combining clinical and pathophysiologic parameters from a Canadian ARDS cohort.
METHODS METHODS
A cohort of adult ARDS patients from multiple sites in Calgary, Canada, had plasma cytokine levels and clinical parameters measured in the first 24 h of ICU admission. We used a latent class model (LCM) to group the patients into several ARDS subgroups and identified the features differentiating those subgroups. We then discuss the subgroup effect on 30 day mortality.
RESULTS RESULTS
The LCM suggested three subgroups (n
PERSPECTIVE CONCLUSIONS
ARDS subgrouping using biomarkers and clinical characteristics is useful for categorizing a heterogeneous condition into several homogenous patient groups. This study found three ARDS subgroups using LCM; each subgroup has a different level of mortality. This model may also apply to developing further trial design, prognostication, and treatment selection.

Identifiants

pubmed: 38745261
doi: 10.1186/s40001-024-01876-7
pii: 10.1186/s40001-024-01876-7
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

284

Informations de copyright

© 2024. The Author(s).

Références

Blank R, Napolitano LM. Epidemiology of ARDS and ALI. Crit Care Clin. 2011;27(3):439–58.
doi: 10.1016/j.ccc.2011.05.005 pubmed: 21742210
Force ADT, Ranieri VM, Rubenfeld GD, et al. Acute respiratory distress syndrome: the Berlin Definition. JAMA. 2012;307(23):2526–33.
MacCallum NS, Evans TW. Epidemiology of acute lung injury. Curr Opin Crit Care. 2005;11(1):43–9.
doi: 10.1097/00075198-200502000-00007 pubmed: 15659944
Bellani G, Laffey JG, Pham T, et al. Epidemiology, patterns of care, and mortality for patients with acute respiratory distress syndrome in intensive care units in 50 countries. JAMA. 2016;315(8):788–800.
doi: 10.1001/jama.2016.0291 pubmed: 26903337
Rubenfeld GD, Caldwell E, Peabody E, et al. Incidence and outcomes of acute lung injury. N Engl J Med. 2005;353(16):1685–93.
doi: 10.1056/NEJMoa050333 pubmed: 16236739
Zilberberg MD, Epstein SK. Acute lung injury in the medical ICU: comorbid conditions, age, etiology, and hospital outcome. Am J Respir Crit Care Med. 1998;157(4 Pt 1):1159–64.
doi: 10.1164/ajrccm.157.4.9704088 pubmed: 9563734
Katzenstein AL, Bloor CM, Leibow AA. Diffuse alveolar damage–the role of oxygen, shock, and related factors. A review Am J Pathol. 1976;85(1):209–28.
pubmed: 788524
Beitler JR, Goligher EC, Schmidt M, et al. Personalized medicine for ARDS: the 2035 research agenda. Intensive Care Med. 2016;42(5):756–67.
doi: 10.1007/s00134-016-4331-6 pubmed: 27040103 pmcid: 4850840
Leisman DE, Ronner L, Pinotti R, et al. Cytokine elevation in severe and critical COVID-19: a rapid systematic review, meta-analysis, and comparison with other inflammatory syndromes. Lancet Respir Med. 2020;8(12):1233–44.
doi: 10.1016/S2213-2600(20)30404-5 pubmed: 33075298 pmcid: 7567529
Sinha P, Matthay MA, Calfee CS. Is a “Cytokine storm” relevant to COVID-19? JAMA Intern Med. 2020;180(9):1152–4.
doi: 10.1001/jamainternmed.2020.3313 pubmed: 32602883
Kollef MH, Schuster DP. The acute respiratory distress syndrome. N Engl J Med. 1995;332(1):27–37.
doi: 10.1056/NEJM199501053320106 pubmed: 7646623
Thille AW, Esteban A, Fernandez-Segoviano P, et al. Comparison of the Berlin definition for acute respiratory distress syndrome with autopsy. Am J Respir Crit Care Med. 2013;187(7):761–7.
doi: 10.1164/rccm.201211-1981OC pubmed: 23370917
Famous KR, Delucchi K, Ware LB, et al. ARDS subphenotypes respond differently to randomized fluid management strategy. Am J Respir Crit Care Med. 2016. https://doi.org/10.1164/rccm.201603-0645OC .
doi: 10.1164/rccm.201603-0645OC
Calfee CS, Janz DR, Bernard GR, et al. Distinct molecular phenotypes of direct vs indirect ARDS in single-center and multicenter studies. Chest. 2015;147(6):1539–48.
doi: 10.1378/chest.14-2454 pubmed: 26033126
Calfee CS, Delucchi K, Parsons PE, et al. Subphenotypes in acute respiratory distress syndrome: latent class analysis of data from two randomised controlled trials. Lancet Respir Med. 2014;2(8):611–20.
doi: 10.1016/S2213-2600(14)70097-9 pubmed: 24853585 pmcid: 4154544
Walter JM, Wilson J, Ware LB. Biomarkers in acute respiratory distress syndrome: from pathobiology to improving patient care. Expert Rev Respir Med. 2014;8(5):573–86.
doi: 10.1586/17476348.2014.924073 pubmed: 24875533
Bos LD, Schouten LR, van Vught LA, et al. Identification and validation of distinct biological phenotypes in patients with acute respiratory distress syndrome by cluster analysis. Thorax. 2017;72(10):876.
doi: 10.1136/thoraxjnl-2016-209719 pubmed: 28450529
Sinha P, Delucchi KL, McAuley D, O’Kane C, Matthay M, Calfee CS. Development and validation of parsimonious algorithms to classify acute respiratory distress syndrome phenotypes: a secondary analysis of randomised controlled trials. Lancet Respir Med. 2020. https://doi.org/10.1016/S2213-2600(19)30369-8 .
doi: 10.1016/S2213-2600(19)30369-8 pubmed: 33075298 pmcid: 7567529
Terpstra ML, Aman J, van Nieuw Amerongen GP, Groeneveld AB. Plasma biomarkers for acute respiratory distress syndrome: a systematic review and meta-analysis*. Crit Care Med. 2014;42(3):691–700.
doi: 10.1097/01.ccm.0000435669.60811.24 pubmed: 24158164
Marbac M, Sedki M. Variable selection for model-based clustering using the integrated complete-data likelihood. Stat Comput. 2017;27(4):1049–63.
doi: 10.1007/s11222-016-9670-1
Marbac M, Sedki M. VarSelLCM: an R/C++ package for variable selection in model-based clustering of mixed-data with missing values. Bioinformatics. 2018;35(7):1255–7.
doi: 10.1093/bioinformatics/bty786
Siddiqi N. Credit risk scorecards: developing and implementing intelligent credit scoring. Hoboken: Willey; 2012.
doi: 10.1002/9781119201731
Metwaly S, Côté A, Donnelly SJ, et al. ARDS metabolic fingerprints: characterization, benchmarking, and potential mechanistic interpretation. Am J Physiol Lung Cell Mol Physiol. 2021;321(1):L79-l90.
doi: 10.1152/ajplung.00077.2021 pubmed: 33949201
Ranjeva S, Pinciroli R, Hodell E, et al. Identifying clinical and biochemical phenotypes in acute respiratory distress syndrome secondary to coronavirus disease-2019. EClinicalMedicine. 2021;34:100829.
doi: 10.1016/j.eclinm.2021.100829 pubmed: 33875978 pmcid: 8047387
Sinha P, Delucchi KL, Thompson BT, et al. Latent class analysis of ARDS subphenotypes: a secondary analysis of the statins for acutely injured lungs from sepsis (SAILS) study. Intensive Care Med. 2018;44(11):1859–69.
doi: 10.1007/s00134-018-5378-3 pubmed: 30291376 pmcid: 6317524

Auteurs

Andréanne Côté (A)

Department of Medicine, Institut Universitaire de Cardiologie et de Pneumologie de Quebec-Université Laval, Quebec, Canada.
Department of Critical Care Medicine, Medicine and Biochemistry and Molecular Biology, Health Research Innovation Center (HRIC), University of Calgary, Room 4C64, 3280 Hospital Drive N.W., Calgary, AB, T2N 4Z6, Canada.

Chel Hee Lee (CH)

Department of Critical Care Medicine, Medicine and Biochemistry and Molecular Biology, Health Research Innovation Center (HRIC), University of Calgary, Room 4C64, 3280 Hospital Drive N.W., Calgary, AB, T2N 4Z6, Canada.
Department of Mathematics and Statistics, University of Calgary, Calgary, Canada.

Sayed M Metwaly (SM)

School of Medicine, Medical Sciences and Nutrition, University of Aberdeen, Aberdeen, UK.
Division of Internal Medicine, Aberdeen Royal Infirmary, NHS Scotland, Aberdeen, UK.

Christopher J Doig (CJ)

Department of Critical Care Medicine, Medicine and Biochemistry and Molecular Biology, Health Research Innovation Center (HRIC), University of Calgary, Room 4C64, 3280 Hospital Drive N.W., Calgary, AB, T2N 4Z6, Canada.

Graciela Andonegui (G)

Depatments of Medicine, University of Calgary, Calgary, Canada.

Bryan G Yipp (BG)

Department of Critical Care Medicine, Medicine and Biochemistry and Molecular Biology, Health Research Innovation Center (HRIC), University of Calgary, Room 4C64, 3280 Hospital Drive N.W., Calgary, AB, T2N 4Z6, Canada.

Ken Kuljit S Parhar (KKS)

Department of Critical Care Medicine, Medicine and Biochemistry and Molecular Biology, Health Research Innovation Center (HRIC), University of Calgary, Room 4C64, 3280 Hospital Drive N.W., Calgary, AB, T2N 4Z6, Canada.

Brent W Winston (BW)

Department of Critical Care Medicine, Medicine and Biochemistry and Molecular Biology, Health Research Innovation Center (HRIC), University of Calgary, Room 4C64, 3280 Hospital Drive N.W., Calgary, AB, T2N 4Z6, Canada. bwinston@ucalgary.ca.
Depatments of Medicine, University of Calgary, Calgary, Canada. bwinston@ucalgary.ca.
Department of Biochemistry and Molecular Biology, University of Calgary, Calgary, Canada. bwinston@ucalgary.ca.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH